Company Profiles, Part 3

of nine

Company Profiles: Evidation Health 1

Evidation Health is a new kind of health and measurement company, providing the largest most innovative biopharma and health care companies the technology required to understand how everyday behavior and health interact. It was founded in 2012 in San Mateo, California, United States and its major products are data platform and studies. The requested information has been entered into column F, rows 3 to 10 in the attached spreadsheet.




  • Evidation Health has received a total funding of $65 million since Aug 1, 2012.
  • The funding status of the company is known as "Late Stage Funding". The last funding was "Series C Funding", raising $30 million.







of nine

Company Profiles: Evidation Health 2

Evidation Health has two licensed technologies, a data analysis platform called Andromeda, and a research service called Observatory. The company has Sanofi, TidePoo, Tueo health, and Eli Lilly & Company as some of its key customers. The requested information on Evidation Health has been compiled in rows 12-17, column F of the “Profiles” tab of the attached spreadsheet.


Evidation Health has the following two licensed technologies:
  • Andromeda Platform — A self-developed platform to process high-frequency medical data into actionable insights. (Source6)
  • Observatory Study Service — A tech-enabled service that conducts real-world research to support medical teams and staff in research.




  • Evidation Health has data for more than 2 million patients.


  • The company stores data on its own platform, Andromeda.
  • Evidation Health has stored information from more than 100 data sources on Andromeda.
  • This data is linked with the patients' electronic health records, insurance claims, and environmental data.
  • The data can be analyzed with queries to generate round the clock analysis and provide research solutions.
of nine

Company Profiles: Evidation Health 3

Evidation Health holds data for Individuals, doctors, and researchers at life sciences, payers and health care providers. The main competitors are Lightbeam Health and Vitreos Health. Details on the profile of Evidation Health have been provided on rows 18-23, column F of the PROFILES tab of the attached spreadsheet. 


  • Individuals, doctors, and researchers at life sciences, payers and health care providers are different types of medical centers/facilities that Evidation Health holds records/data for.
  • Although the terms of agreement with medical centers are undisclosed, Evidation Health has multi-year agreement to provide Lilly with global access to its Andromeda data platform. Lilly scientists leverage Evidation’s Andromeda platforms to gain "instant access to a private, collaborative, and secure analytical environment where they can use powerful algorithms to process raw data for use in clinical studies or to create their own predictive models."
  • Lightbeam Health and Vitreos Health are competitors of Evidation Health.
  • Evidation Health uses Andromeda data platform to turn raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease.
  • The data platform allows to set up secure, private instance or a single or multiple studies, with hundreds of pre-built connectors or custom ingestion.



To provide this information, your research team scoured through Evidation Health's website and industry databases such as Bloomberg and ZoomInfo to find the types of medical centers it serves.


To identify how the medical center may access stored data, we scanned through the press release section of Evidation Health's website for an announcement on collaborations. The restrictions pertaining to data usage were clearly stated as prohibitions under the "Terms of Use" section of the website.


We leveraged industry databases such as CrunchBase to determine competitors. For each identified competitor, we proceeded to view the overview and service offerings of the companies in their respective websites to confirm that they either use data to improve patient identification and recruitment for clinical trials or have secured access to large amounts of healthcare data (EMR, claims data, pharmacy data). Additionally, the number of employees for the identified competitors and Evidation Health is less than 100, which implies that the companies are of similar scale.


This information was garnered from the product section of the company's website.

Competitors In Europe/Asia

To identify Evidation Health's competitors in Europe or Asia, we scoured through Evidation Health's website, press releases, white papers, case studies, and others. While there was information pertaining to the company's product line and research papers, none of the found resources threw light on the competitors of the company. We also searched for the annual report of the company which often provides competitor information, however, no competitor was provided. Furthermore, we looked up for the company profile of Evidation Health from credible industry databases such as Hoovers, Crunchbase, Craft, ZoomInfo, and others. Most of the databases identified competitors that are located in the U.S. with none from Europe or Asia.
of nine

Company Profiles: Cota Health 1

Cota Healthcare was founded in 2011. Quoted on the New York Stock Exchange, Cota is present in the United States and " more than 100 countries" with over 55,000 employees and several customers. Cota has offices in New York and Cambridge. Additional details on the company Profile of Cota Health are found in the attached spreadsheet.

1. Cota Health

  • The website of Cota healthcare is accessible via this link.

Funding History

Management Hierarchy: CEO

  • Michael Doyle is the President and CEO of Cota Healthcare.
  • Michael Doyle attended the University of Chicago Booth School of Business between 1980 – 1982 and graduated with an MBA in Hospital Administration and Finance.
  • Michael Doyle attended Tufts University where he obtained a BS Field in Biology and Community Health between 1976 and 1980. He was the President and CEO of QPID Health an eviCore Company Express Scripts Company from Dec 2012 to Sep 2018.

Management Hierarchy: Founder & executive chairman

  • The founder, as well as executive chairman of Cota healthcare, is Dr. Andrew L. Pecora.
  • Dr. Pecora is a Professor of Medicine, with the UMDNJ-New Jersey Medical School, and also a Professor of Oncology and Medicine with the Georgetown University.
  • Dr. Pecora co-founded Progenitor Cell Therapy, L.L.C.; and Amorcyte, Inc. He holds a B.S. from the Seton Hall University and obtained an M.D. from the University of Medicine and Dentistry, New Jersey.
  • Dr. Pecora completed his internship and residency with the New York Hospital-Cornell Cooperating Hospitals System as well as a fellowship in hematology/oncology with the Memorial Sloan-Kettering Cancer Center.
  • Additional details on the company Profile of Cota Health are found in the attached spreadsheet.


Our research team scoured through the website of Cota Health, recent news articles in the health industry, the LinkedIn pages of management Cota Health staff among other resources to gain precompiled insights into its company profile. Our strategy was mostly straightforward. However, despite detailed research, we could not uncover the prices of Cota Healthcare products as potential customers need to contact Cota healthcare to request demo and pricing models available. We could not gain insights into all countries that Cota Health currently operates.

Further research through comparative analysis websites such as Crunchbase, Zoom, among other databases, failed to uncover insights into all countries that Cota Health currently operates or the comprehensive list of Costa Health products and their prices. Insights obtained from Crunchbase revealed the lead investors and funding rounds of Cota. Detailed research through health trade journals such as the American Journal of Occupational Therapy (AOTA), Drug Store News among other resources for Cota Health company profile failed to uncover the prices and list of Cota Healthcare products. There was no significant finding into the list of countries that Cota Health currently operates. Insights obtained from the Drug Store News website revealed that Cota Health recently partnered with Novartis.

Research through Cota website for the list of C-level and key/vital technical employees revealed the names of C-level and key staff. However, Cota Health website did not give insight into staff work history and education. We researched through professional databases such as LinkedIn among other databases to uncover the work history and educational attainment of the identified C-level and vital technical staff. No profile of Kevin Wells and Sudhakar Velamoor the Vice Presidents of Engineering, had any mention of the company Cota health. As a triangulation attempt, since insights obtained from the Linkedin profile of Kevin Wells worked as a healthcare consultant and has functioned as a VP of operations before, we concluded that the Linkedin profile is that of a Cota Health staff.

of nine

Company Profiles: Cota Health 2

The technologies licensed by Cota Healthcare are CNA (Cota Nodal Address), Influx, and five different patents for "clinical outcome tracking and analysis". Their main customers include Novartis Pharmaceuticals Corporation, HelthScape Advisor, and Celgene. The data maintained by Cota includes electronic medical records (EMR) of users, medical professionals, experts, public (demographic) databases, and data from any online source. The 2,000,000 data retained is stored through a variety of methods, including screening, results tracking, and performance status of the Eastern Cooperative Oncology Group (ECOG).

The link to the spreadsheet is here.

Technology license

  • Cota Nodal Address (CNA) — Software that organizes the files of big data to determine information of medical interest, through a control code.
  • Influx — Software by which Cota acquires, processes, and structures the data. It extracts important information from unstructured data to be interpreted by the CNA.
  • And, the company has five different patents for "clinical outcome tracking and analysis".

Key clients

data storage

  • Cota stores the electronic medical records (EMR) of users, medical professionals, experts, public databases, and data from any online source.

The amount of data held by the company

  • Currently, CotaHealthcare estimates that its database has 2,000,000 patients.

Different methods of data storage

  • The Cota data storage parameters include screening, tracking results, and analyzing the performance status of the Eastern Cooperative Oncology Group (ECOG), checking the toxicity to therapy, and cost of care.
  • Each Cota data record includes data associated with an illness and data associated with patients currently with the disease or patients who have had the disease.
  • The Cota module can allow the users to perform multiple analysis on one or more of the data records, which are stored through their specifications.
  • The Cota nodal address (CNA) code, indicating one or more variables, is applied to the patient's medical records ordered set to determine a clinically relevant set of patient medical records such as the patient's medical records sorted by satisfying one or more variables.
  • Each CNA is represented as a discrete punctuated sequence of digits comprising a prefix, a medium, and a suffix representing a set of preselected variables that divide the classified information into a clinically relevant set of health information.
  • The Cota module tracks the consequences of treatment choices and report results associated with the use of Cota Node Addresses (CNAs).
of nine

Company Profiles: Cota Health 3

Cota Health has a patented Cota Nodal Address (CNA) system, which is a unique digital classification methodology built by leading physicians and data scientists. It is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale. Cota Health also recently signed a multi-year agreement with Memorial Sloan Kettering Cancer Center (MSK) which is one of the world's most renowned cancer centers. Some of Cota's competitors include BostonGene, PierianDx, EarlySense, Bluebee, Flatiron Health, and DNAnexus. All the information has been entered in the attached spreadsheet.

  • Cota Health works with health providers (which may include hospitals, clinics, private practices), payers, life sciences companies, patients, and the Food and Drug Administration.
  • Cota Health has signed a multi-year agreement with Memorial Sloan Kettering Cancer Center (MSK) which is one of the world's most renowned cancer centers.
  • There is a technological collaboration between MSK and Cota Health that is focused on advanced analytics to enable more consistent disease classification within oncology thus helping to drive further insights for both researchers and physicians.
  • Through its unique classification system, the Cota Nodal Address (CNA), Cota will construct optimized clinical and genomic datasets from the MSK records. The resulting datasets will help MSK improve patient care and advance its world-leading research efforts.
  • The CNA is the first and only system that precisely categorizes patient factors, their diseases, and intended therapies, which enables precision medicine at scale.
  • Cota Health also uses Google Analytics to collect visitor information so that they can better understand how to improve their products and services.
  • Cota Healthcare uses 10 technology products and services in total including Google Analytics, G Suite, formerly known as Google Apps for Work, and Microsoft Office 365.
  • Cota Healthcare competes with BostonGene, PierianDx, EarlySense, Bluebee, Flatiron, Health and DNAnexus.
  • EarlySense is a Jewish company while BlueBee is a European company based in the Netherlands.

Research Strategy:

In conducting the search for competitors to Cota Healthcare in the US, Asia and Europe, we took advantage of a compilation of leading publications, expert blogs and reviewers, industry databases to put together the competitors to Cota Healthcare in the US. We started by searching for competitors to Cota Healthcare globally and we found quite a good deal of information. We then focused our search to the US portion of the company and then moved on to Asia and Europe. We found Cota's competitors, revenue, number of employees, funding, and acquisitions published by Owler. The list included the following companies: Synapse, BostonGene, DNAnexus, Ariel, Bluebee, EarlySense, Flatiron, and GenoSpace. We confirmed the list against other company databases like Crunchbase and PRNewswire.

of nine

Companies Acquired, Pt. 1

Merge and Phytel were both acquired by IBM in 2015. In 2017, IMS health and Quintiles Transnational Holdings announced the merging and became Iqvia and is not acquired by any company since then. The overview of these acquisitions is outlined below and detailed in Column C-E of the attached spreadsheet.




  • IBM acquired Phytel at an undisclosed amount on May 4, 2015.
  • The Phytel's acquisition will allow primary care providers, physician networks, and large hospital systems to improve healthcare quality and effect healthier patient outcomes with the use of IBM's advanced analytics and cognitive computing system.
  • Mike Rhodin, senior vice president of IBM Watson, stated that the acquisition of Phytel would support the vision of the company to improve the quality and effectiveness of personal healthcare by allowing secure access to customized insights and a complete picture of the factors that might affect people's health.
  • Nationwide, Phytel's state-of-the-art registry had 20 million patients before the acquisition.

Research Strategy:

To find the requested information, our research team started our search by looking through company websites, LinkedIn profiles, company profiles in third-party websites like CrunchBase, and several other business news publications like PR Newswire and BusinessWire. While we were able to find all the requested details for Merge and Phytel except their number of patients before the acquisition.
As IBM acquired Phytel in 2015, we switched our gears and tried to filter the search result for the year 2012-2014, However, after an extensive search through every result regarding Phytel Inc, we were not able to find any details about their number of patients and customers. We again lowered our the custom range into 2011-2014 and were finally successful in finding their total number of patients based on 2011 press released from BusinessWire.
For IQVIA, based on their company website, business media publications, and CrunchBase profile of Iqvia, we determined that they are not acquired by any company. The only information we could find was that IMS health and Quintiles Transnational Holdings announced the merging and became Iqvia in 2017. Therefore, we put N/A for Column C of the attached spreadsheet.

of nine

Companies Acquired, Pt. 2

In 2015, IBM acquires Explorys — IBM acquired Explorys as part of the company in establishing Watson Health Cloud providing secure and open platform for medical professionals, insurers, and related companies in health and wellness space — prior to acquisition, Explorys offers a secure software platform that allows healthcare systems to summarize, analyze, and manage data.

In 2016, IBM acquires Truven Health Analytics — IBM acquired Truven Health Analytics to use its cognitive healthcare abilities in improving patient health outcomes, advancing value-based care solutions, and controlling healthcare costs — prior to the acquisition, the company's key product offerings were advantage suite data, market scan, micromedex, and action OI.

In 2019, Dassault Systemes acquires MedidataDassault Systemes acquired Medidata with the goal of strengthening its life science field — prior to acquisition, the company products were studied conduct, data management like medical coding; analytics like biomarker analysis, shyft analytics, trial planning like study design, targeted SDFV, trial management like site payments, RBM, and platform/platform tools like Medidata enterprise data store.

Our research team has completed rows 3-8, columns F-H of the acquisition tab of the attached spreadsheet.


  • In 2015, IBM acquired Explorys at an undisclosed amount.
  • IBM's acquisitions of four companies which include Explorys cost more than $4 billion.
  • IBM acquired Explorys as part of the company in establishing Watson Health Cloud which provides a secure and open platform for medical professionals, insurers, and related companies in the health and wellness segment.
  • Prior to the acquisition — Explorys offers a secure software platform that allows healthcare systems to summarize, analyze, and manage data.


  • In 2016, Truven Health Analytics was acquired by IBM amounting to $2.6 Billion. (s8)
  • Based on Truven's former annual report, the company's key product offerings were advantage suite data, marketscan, micromedex, and action OI. (s9, corroborated by s10)


  • Medidata was acquired by Dassault Systemes on June 12, 2019, in the deal amounting to $5.8 billion.
  • The expertise of Medidata in clinical trials and of cloud-based solutions power the development and commercialization of smarter therapies have been the most important factor for Dassault Systems especially it matches their goal of strengthening its position in life sciences industry.
  • Medidata product where study conduct — medical imaging and virtual trials; data management — medical coding; analyticsbiomarker analysis, SHYFT analytics; trial planning — study design, targeted SDFV; trial management — site payments, RBM; and platform/platform tools — Medidata enterprise data store.


We began by combing through companies websites, annual reports, industry reports, press releases, and third-party databases for information regarding acquisition details of Explorys, Truven, and Medidata. Our research team went further to comb through older reports locating the acquisition date of Explorys and Truven. Our research team has completed rows 3-8, columns F-H of the acquisition tab of the project spreadsheet.
of nine

Companies Acquired, Pt. 3

Our research team has completed rows 3-8, column I - K of the Acquisitions tab, which provides details regarding the acquisition of companies Symphony Health, Anolinx, Foundation Medicine, and Flatiron, in the attached spreadsheet. Symphony Health was acquired in 2017 by PRA Health for $530 million, Anolinx was acquired by Parelex in 2017 for an estimated $174 million, and Roche acquired both Foundation Medicine and Flatiron in 2018, for $5.3 billion and $1.9 billion, respectively. At the time of acquisition, Flatiron had approximately 2.2 million patient records, while Foundation had patient data for approximately 300,000 individuals.

Flatiron Health

  • Roche acquired Flatiron Health in April 2018 for a value of $1.9 billion.

Valuation Factors

  • Flatiron's data analysis approach is seen to allow for the comparison of oncology drugs outside of the clinical trials environment, thus enabling a "value-based pricing" model for said drugs.
  • Flatiron's data analytics capabilities and integration with oncology clinics, practitioners, companies, and academic/federal laboratories is seen as giving the company a decided advantage in terms of being able to streamline the clinical trials process for Roche's therapeutic oncology drugs. By connecting the right patients to the right clinical trials, Flatiron's capabilities may enhance the efficacy of drugs that make it to the market.

Patient Records and Customers

  • At the time of acquisition, Flatiron had approximately 2.2 million patient records and partnerships with 15 major companies, 7 research institutions, and its 2,600 OncoEMR system users.


Foundation Medicine

  • Roche acquired Foundation Medicine in June 2018, and the company was valued at $5.3 billion at the time.

Valuation Factors

  • Foundation's genome sequencing and matching technology allows for the alignment of a patient's specific cancer traits to immunotherapy drugs to achieve maximum efficacy.
  • Before 2017, Foundation had struggled to generate uptake of its technology amongst insurance payers and oncologists. However, through the U.S. Food and Drug Administration's approval of their diagnostic tool, Foundation One CDx, and recent support from the U.S. government for the use of genomic sequencing tools in cancer treatment, sales have increased considerably.

Patient Records and Customers

  • At the time of acquisition, Foundation had patient data for approximately 300,000 individuals, as well as around 30 biopharmaceutical industry partners.



Valuation Factors

Patient Records and Customers

  • While no specific number exists for Anolinx's total customers, it is known that Anolinx was working with AstraZeneca on a 50 private practice, ambulatory clinic, and outpatient clinic assessment of their EMR tools. In addition, Anolinx was working with United States Department of Veterans' Affairs Salt Lake City facility, serving some 57,000 veterans, before its acquisition.


  • Anolinx's primary products were Big Data analytics to assess the competitive nature of clinical trial protocols, and EMR/EHR records analysis for clinical trials optimization.

Symphony Health


  • Pharmaceutical Research Associates paid about $530 million in cash for the outstanding equity of Symphony Health. The company had just revamped their IT infrastructure which became very scalable, and "being on one platform gives them the agility and nimbleness to provide customized data solutions.

Patient Records and Customers

  • Symphony Health’s main asset is a data service called Integrated Dataverse, a collection of claims data and prescriber information for 280 million patients and 1.8 million prescribers in the US.


  • Symphony Health's products and services included Integrated Dataverse, high-value data, analytics, technology solutions, and connecting and integrating health data and analytics delivered as cloud-based solutions.

Research Strategy:

  • Starting with each respective company and the requested inputs, we conducted a series of searches examining the company's acquisition, its services and sector, and other relevant publications addressing the company's value to the pharmaceutical and biopharmaceutical sector. This approach yielded information for each company in alignment with the client's request except Anolinx. For some of these data points, out of date sources were used and this was necessary to capture the relevant historical information about two of the companies, Symphony Health and Anolinx, as both were acquired in 2017.
  • After an exhaustive search of credible sources on Anolinx, including startup company databases, annual reports (SEC 10-Ks) from the acquiring company, Anolinx's website and social media profiles (either no longer functioning or not used), and research papers, we were unable to find a specific dollar amount valuation, amount of patient data handled, or number of customers at the time of acquisition. To address the first point, we broadened the research strategy to include all financial information pertaining to Anolinx, searching various databases, such as Crunchbase, to gather information such as annual revenue, and sales. This approach yielded an annual revenue estimate for Anolinx, and the information was used to triangulate a value of the company based on the ratio of an analogous company's annual revenue to valuation at time of sales.
  • According to The Hartford, and supported by Ben McClure of Investopedia, when a valuation number is unavailable for a firm at the time of sale, one can use the ratio of valuation to annual sales for an analogous company in the same market, to create a multiplier that allows for estimating the value of the aforementioned first firm.


  • Anolinx Value = Anolinx Estimated Annual Revenue (source 25)*(Foundation Medicine Valuation (source 9)/Foundation Medicine Annual Revenue at time of Sale). Anolinx Value = $5,000,000*($5,300,000,000/$152,000,000) = $174,342,105.
  • After triangulating the value of Anolinx, we searched for references to the company in relationship to patient or customer data. This initial search did not yield any definitive information either. We first searched through credible databases, looking through major startup databases like Crunchbase, Owler, and AngelList. We searched for information pertaining to patient data and customers, however, these databases did not yield any information, and most had little to no information about Anolinx, its employees, or their key products and services.
  • After being unable to find any information in major startup databases, we expanded the research criteria to focus on identifying any mention of patients, patient data, or partnerships (in lieu of customers) that referenced Anolinx. This approach yielded references to two partnerships, one with AstraZeneca and another with the U.S. Veterans' Administration, however there were no specific tallies of patient data or total customers. We however managed to find a tally for a single source resulting from the AstraZeneca partnership.
  • Data concerning the amount of patient data available was limited, and the sources that could be used for rough triangulation, such as patient data available to AstraZeneca and the VA, are expansive systems and it was unclear based on the sources found how much Anolinx had access to customer data. What was available was a 2016 estimate, the most recent report from the VA, of the number of patients served by the US Veterans' Administration facility in the Salt Lake City, UT area where Anolinx was conducting its primary partnership. This value has been supplied as a partial estimate of the total potential patient records available to Anolinx before its acquisition.

From Part 01
  • "Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors"
  • "GE Ventures and Stanford Health Care have teamed up to create Evidation Health, a company focused on evaluating the efficacy of digital health technologies. Soon after Evidation was formed it merged with wellness engagement platform company The Activity Exchange"
  • "“Our new data platform makes it easier for statisticians and data scientists at life sciences and health care companies to take everyday behavior and health care data, analyze it, and create a new understanding of health,” said Evidation Health CEO Deborah Kilpatrick, Ph.D. “This will help Evidation speed a transformation in real world research and knowledge, so we can better treat, diagnose, and predict the onset of disease.”"
  • "A technology-enabled service for conducting real world research that incorporates novel, everyday behavior data to support clinical, medical affairs, and commercial teams, leveraging Evidation's virtual site."
From Part 03
  • "Lightbeam's value-based care services offer complete end-to-end consultation to support your organization from patient recruitment to care management."
  • "The Lightbeam platform combines patient data from multiple sources so you can analyze and identify opportunities within your patient population to reduce costs, improve health outcomes, and generate revenue. Lightbeam unlocks the value found in patient data by providing you the right data in the right place at the right time."
  • "As a pioneer of Advanced Population Health analytics for Big Data, we leverage the broadest set of data sources including EHR, claims, HRAs, socioeconomic and well-being data for predictive risk and prescriptive care management."
From Part 06
  • "“COTA was founded in 2011 by oncologists, engineers, and data scientists, with one aim in mind: to transform cancer care so that every patient gets the right treatment. That’s not a mission we can achieve alone."
  • "We are very excited to partner with Memorial Sloan Kettering, one of the world's leading cancer centers, and merge their unmatched experience in cancer research and patient care with our innovative approach to data analytics," said John Hervey, chief executive officer of Cota. "
  • ""By combining the precision of our Cota Nodal Address system with Memorial Sloan Kettering's robust datasets, clinical expertise and outstanding record of success, together we will advance how the industry leverages data analytics to improve cancer patient care.""
  • "Cota builds solutions for healthcare to analyze, visualize, report, and manage real-world evidence and deliver precision medicine. New York, New York, United States"
  • "Cota's technology enriches raw medical records to create research-grade data, and joins it with a suite of analysis, visualization, and management tools. This enables providers, payers, and life sciences companies to analyze, report on, and research outcomes, costs, treatments, and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and science to help improve the lives of patients everywhere. "
  • "COTA collects and holds personal information in relation services it offers. Where it is possible, we collect your personal information directly from you in person, in writing, over the telephone, by facsimile, through our online services and/or by electronic messages. In some circumstances, we may also collect it from: "
From Part 08
  • "With a goal of advancing the quality and effectiveness of personal healthcare, IBM is establishing a Watson Health Cloud to provide a secure and open platform for physicians, researchers, insurers, and companies focused on health and wellness solutions."
  • "The HIPAA-enabled Watson Health Cloud will enable secure access to individualized insights and a more complete picture of the many factors that can affect people’s health."
  • "To complement its existing capabilities, IBM has reached agreement to acquire Cleveland-based Explorys and Dallas-based Phytel, two healthcare technology companies that apply Big Data and analytics to help improve the quality of health for individuals and large population groups."
  • "The acquisitions bolster IBM’s efforts to apply advanced analytics and cognitive computing to help primary care providers, large hospital systems and physician networks improve healthcare quality and effect healthier patient outcomes."
  • "In 2015, IBM purchased healthcare data analytics-firm Explorys and patient communications company Phytel for an undisclosed amount. In 2016, IBM acquired Truven Health Analytics for $2.6 billion."
  • "Upon completing all three acquisitions, IBM boasted its Watson Health Cloud housed "one of the world's largest and most diverse collections of health-related data, representing an aggregate of approximately 300 million patient lives acquired from three companies.""
  • "At least one of those acquisitions, Truven, was recently cited by IBM's Kelly as key to moving insurance provider data onto the IBM Watson Health platform now that it's going to be offered through a hybrid cloud."
  • "The staff keeps growing because business is booming. In addition to six major healthcare providers, including Cleveland Clinic, University Hospitals, Summa Health System, MetroHealth, St. Joseph Health System and MedStar, the company added four additional providers -- Catholic Health Partners, Iowa Health System, Venture Health and Legacy Health -- for a total of 13 integrated health systems serving 31 million patients."
  • "The company, which was spun out of the Cleveland Clinic, offers a secure software platform that allows healthcare systems to summarize, analyze and manage data."
  • "Explorys launched new solutions to its Enterprise Performance Management (EPM) package of applications that help customers identify gaps in services and improve patient care. “We’ve provided that infrastructure and technology to reach out to those patients,” explains Lougheed. “We’re seeing patterns in the market and we’re using those patterns to develop new products.”"
  • "Truven will bring more than 8, 500 clients, including U.S. federal and state government agencies, employers, health plans, hospitals, clinicians and life sciences companies to the IBM Watson Health portfolio."
  • "Upon completion of the acquisition, IBM’s health cloud will house one of the world’s largest and most diverse collections of health-related data, representing an aggregate of approximately 300 million patient lives acquired from three companies1. "
  • "IBM plans to integrate Truven’s extensive cloud-based data set spanning hundreds of different types of cost, claims, quality and outcomes information with its existing data sets."
  • "Data and insights from Truven inform benefit decisions for one in three Americans. Upon close, the acquisition of Truven will bolster Watson Health’s global talent footprint to more than 5, 000 employees, including hundreds of clinicians, epidemiologists, statisticians, healthcare administrators, policy experts and healthcare consultants who will join the IBM business unit. Truven’s cloud-based technology, methodologies and health claims data will be integrated into the Watson Health Cloud over time."
  • "Truven Health Analytics owns some of the most trusted brands in healthcare, such as MarketScan®, 100 Top Hospitals®, Advantage Suite®, Micromedex®, Simpler, ActionOI® and JWA. Truven has its principal offices in Ann Ar-bor, Mich.; Chicago; and Denver. For more information, please visit"
  • "Our data assets totaled 4.5 petabytes of data including approximately 30 billion claims records on over 214 million de‑identified patient lives."
  • "Our 4.5 petabytes of online data represents a collection of some of the most comprehensive data assets in the industry, such as one of the largest collections of commercially insured patient data, one of the largest databases of operational benchmarks and clinical performance data for hospitals and one of the most comprehensive databases of evidence‑based clinical decision support content."
  • "Dassault Systemes added that the takeover would strengthen its position in the life sciences field."
  • "“Medidata’s leading position in clinical trials complements our life sciences solutions on the 3DEXPERIENCE collaborative platform,” said Dassault Systemes CEO Bernard Charles."
  • "Medidata had 2018 revenue of $636 million, and Dassault Systemes expects to close the acquisition during the fourth quarter of 2019."
  • "Medidata Solutions’ market-leading clinical cloud solutions are used by 1,300 customers worldwide to develop their therapeutic innovations and clinical operations performance "
  • "With the acquisition of U.S.-based Medidata and its clinical and commercial solutions, Dassault Systèmes will reinforce its position as a science-based company by providing the Life Sciences industry with an integrated business experience platform for an end-to-end approach to research and discovery, development, clinical testing, manufacturing and commercialization of new therapies and health technologies."
From Part 09
  • "The Hartford is a longstanding investment firm with experience in a variety of sectors."